My questions to the board were based on my years of experience using adenovirus viral vectors for genetic insertions. I think the questions I posed are relevant and so I appreciated MGK_2 taking the time to consider them, given that they could potentially lead to a better understanding of LL.

Having said that, I’m not sure if the anti-LL antibodies are being produced in response to the way LL is being packaged as they exit the myocytes or in response to the original introduction to the AAV - but I don’t remember anti-LL antibodies being that much of an issue (if at all) with sub-q LL and that’s why I ponder if adding sub-q LL might add therapeutic benefit.

Thanks for your response, MGK_2. It was helpful.